Cymbalta® Withdrawal Help

We are no longer accepting new Cymbalta withdrawal cases.

cymbalta unsealed documents

Zantac cancer lawsuit lawfirm

Withdrawing from Cymbalta can cause severe, long-term adverse effects. It is important to seek Cymbalta withdrawal help when coming off of an antidepressant such as this. An estimated 44% to 78% of people who stop taking Cymbalta will suffer withdrawal reactions, and of those, 9.6% to 17.2% will suffer severe withdrawal symptoms, according to an Eli Lilly study.

This web page contains links to websites owned and operated by third parties. This information is solely for informational purposes. IT IS NOT INTENDED TO PROVIDE MEDICAL ADVICE. Baum Hedlund does not take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading or following the information contained in this information. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Before undertaking any course of treatment, the reader must seek the advice of their physician or other health care provider.

Before stopping any medication you must first consult with your healtcare provider.

Cymbalta Withdrawal Help: Online Resources and Articles About Antidepressant Withdrawal

Inner Compass Initiative provides information, resources, tools, and connecting platforms ​to facilitate more informed choices regarding all things “mental health” and to support individuals and groups around the world who ​wish to leave, bypass, or build community beyond the mental health system.

The Withdrawal Project-TWP Connect is a free online platform created by and for people who are thinking about, in the process of, or have past experiences with partially reducing or fully coming off psychiatric drugs.

Harm Reduction Guide to Coming Off Psychiatric Drugs and Withdrawal

Coming Off Psychiatric Medication, “Selective Serotonin Re-uptake Inhibitors”

Drug Informer, “Duloxetine Hydrochloride”

Coming Off Psych Drugs (Documentary)

PsychCentral, “6 Ways to Prepare for Withdrawal from an Antidepressant” Cymbalta Information, “RxISK Stories: Withdrawal from antidepressants – V’s story”

David Fox, “My Story and My Fight Against Antidepressants,” October 12, 2013

QUARTER WATCH REPORT, “Withdrawal Symptoms and Duloxetine (CYMBALTA), Oct. 3, 2012

Jill Littrell, Ph.D., “Response to 60 Minutes,” February 22, 2012

Peter Breggin, M.D., “Today’s Greatest Mental Health Need:
Psychiatric Drug Withdrawal Programs,” October 18, 2012

The People’s Pharmacy, “Duloxetine (Cymbalta) Side Effects & Withdrawal”

WebMD’s Big Lie

Worst Pills, Best Pills – A review of duloxetine (Cymbalta) – Dangerous side effects and warnings

How Effective are Antidepressants?

60 Minutes, “Treating Depression: Is There a Placebo Effect?” February 19, 2012.

Erick H. Turner et al., “Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy,” The New England Journal of Medicine (2008); 358:252-260.

Irving Kirsch et al., “Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration,” PLOS Medicine, February 2008, Volume 5, Issue 2, e45

H. Edmond Pigott, “STAR*D: A Tale and Trail of Bias,” Ethical Human Psychology and Psychiatry, Vol. 13, No. 1, 2011.

Begley, “The Depressing News About Antidepressants,” Newsweek Magazine, January 28, 2010

The Chemical Imbalance Theory

Philip Hickey, Ph.D., “Psychiatry Did Promote the Chemical Imbalance Theory”

Todd B. Kashdan, Ph.D., “What Causes Depression? Myths About Chemical Imbalances,” March 13, 2014

Blease, “The Duty to be Well-Informed: The Case of Depression,” J. Med. Ethics, April 26, 2013

Marcia Angell, M.D., (former Editor in Chief of the New England Journal of Medicine) “The Epidemic of Mental Illness: Why?” New York Review of Books, June 23, 2011

Jonathan Leo, Ph.D., Jeffery Lacasse, Ph.D., “Psychiatry’s Grand Confession,” January 23, 2012

Consider the Source (ghostwriting medical literature)

Bosch X, Esfandiari B, McHenry L (2012), “Challenging Medical Ghostwriting in US Courts,” PLOS Med 9(1): e1001163.

McHenry, “Of Sophists and Spin-Doctors: Industry-Sponsored Ghostwriting and the Crisis of Academic Medicine,” MSM (Jan-Dec; 2010)

Cymbalta Withdrawal Legal Documents

Glenmullen_Joe_Harvard_MagHere, Dr. Glenmullen states that the risk rates set forth in Lilly’s own analysis are only the tip of the iceberg. The manner in which Lilly evaluated withdrawal in its own studies of Cymbalta would not have captured all of the patients experiencing withdrawal. In fact, based on Cymbalta’s comparatively short half-life, the withdrawal rate is more likely to be in the range of 66% to 78%.

Cymbalta withdrawal lawsuits summary: Personal injury lawsuits filed across the US, claim Cymbalta manufacturer, Eli Lilly and Company, misled them about the antidepressant’s propensity to induce withdrawal side effects and that, when stopping the medication, they suffered withdrawal symptoms including electric-shock like sensations in their body and brain (also known as “brain zaps”), dizziness, nausea, vomiting, vertigo, excessive sweating, insomnia, nightmares, and diarrhea.

Cymbalta Withdrawal Help: Facebook Pages

Cymbalta (SSRI) Withdrawal Forum

Cymbalta Class Action Lawsuit

Cymbalta Withdrawal Studies

David G. Perahia et al., “Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder,” Journal of Affective Disorders, 2005 Jan 1;89:207-212.

Glen I. Spielmans, “Duloxetine does not relieve painful physical symptoms in depression: a meta-analysis,” Psychotherapy and Psychosomatics, 2008; 77(1): 12-16.

Cymbalta Clinical Trials